Polypeptides targeting epidermal growth factor receptor

By developing polypeptides with specific amino acid sequences and using phage display technology, the problem of insufficient affinity in the development of existing EGFR target therapeutic drugs is solved, and high affinity and stable EGFR-targeted polypeptides are provided to meet clinical needs.

CN118878624APending Publication Date: 2024-11-01TONGYI PHARMACEUTICAL (HEFEI) CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410948959.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-15
Publication Date
2024-11-01

AI Technical Summary

Technical Problem

The development of existing EGFR targeted oncology drugs has not yet met clinical needs, and there is a lack of polypeptide-targeted drugs with high affinity with EGFR.

Method used

A polypeptide has been developed that contains a specific amino acid sequence with high affinity with EGFR and is screened and optimized by phage display technology to obtain polypeptide sequences that can specifically bind EGFR for the development of targeted drugs.

Benefits of technology

It provides a polypeptide with extremely strong EGFR affinity and high specificity, with small molecular weight and stable properties, which can provide strong support for the development of EGFR target drugs and surpass the affinity performance of existing polypeptides.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The invention relates to the technical field of biology, in particular to polypeptide targeting an epidermal growth factor receptor. The polypeptide comprises an amino acid sequence as shown in any one of the following (a)-(c): (a) an amino acid sequence as shown in any one of SEQ ID NO.1-4; (b) an amino acid sequence which has epidermal growth factor receptor affinity activity and is obtained by substituting, deleting or adding one or more amino acids in the amino acid sequence as shown in any one of SEQ ID NO.1-4; and (c) an amino acid sequence which has epidermal growth factor receptor affinity activity and has at least 70%, 80%, 90%, 95%, 97%, 98% or 99% sequence identity with the amino acid sequence shown in any one of SEQ ID NO.1-4. The polypeptide has relatively small molecular weight, has extremely strong affinity to EGFR, and can be used as a development basis of drugs taking EGFR as a target spot.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of biotechnology, and in particular to a polypeptide targeting epidermal growth factor receptor. Background Art

[0002] Epidermal Growth Factor Receptor (EGFR) is a member of the Human Epidermal Growth-Factor Receptor (HER) family. In addition to EGFR (also known as ErbB1, HER1), this family also includes HER2 (also known as ErbB2, NEU), HER3 (also known as ErbB3) and HER4 (also known as ErbB4). This family plays an important regulatory role in cell physiological processes, and has the function of binding to extracellular ligands and transmitting signals into cells and activating intracellular signaling pathways.

[0003] EGFR is a multifunctional transmembrane glycoprotein widely distributed on the cell membranes of various tissues in the human body. It consists of three parts: the extracellular domain (N-terminus), the transmembrane domain (hydrophobic α-helical structure) and the intracellular domain (C-terminus). It is a tyrosine kinase receptor with a molecular weight of about 170KDa. Currently known ligands of EGFR include epidermal growth factor (Epidermal Growth Factor, EGF), transforming growth factor α (Transforming Growth Factor α, TGFα), amphiregulin (AREG), β-cell factor (Betacellulin, BTC), heparin-binding EGF-like growth factor (Proheparin-binding EGF-likegrowth factor, HB-EGF) and epidermal regulator (Epiregulin, EREG). EGFR is activated by binding to ligands. Activated EGFR can transmit proliferation signals and anti-apoptotic signals to the cell nucleus through multiple downstream signal transduction pathways such as PI3K-AKT-mTOR, Ras-Raf-MEK-ERK1 / 2, and control cell growth and division. Ligands bind to the extracellular domain of EGFR to form homo- or hetero-dimers. After dimerization, EGFR receptor autophosphorylation occurs, and the autophosphorylation sites include Y992, Y1045, Y1068, Y1148, and Y1173. Autophosphorylation of these sites can guide downstream phosphorylation and activate its kinase pathway in the cell, inducing cell proliferation.

[0004] Studies have shown that EGFR is highly expressed or abnormally expressed in many solid tumors, and the overexpression of EGFR is associated with the metastasis, infiltration, and poor prognosis of tumor cells. Therefore, the development of drugs targeting EGFR is of great significance for the treatment of tumors. Surveys show that EGFR has become a hot target for the development of innovative drugs worldwide. The idea of ​​developing many anti-tumor drugs is to inhibit EGFR activity, prevent its phosphorylation, and then inhibit the activation of downstream signaling pathways, thereby achieving anti-tumor effects. At present, the drugs that target EGFR for the treatment of tumors are mainly small molecule tyrosine kinase inhibitors (TKI) and EGFR monoclonal antibodies. Although the development of related drugs has made great strides in recent years, the related drugs currently on the market still cannot meet market demand.

[0005] Compared with proteins with larger molecular weight, peptides with smaller molecular weight have the advantages of stable properties, easy synthesis, modification and optimization, and high product purity, and are one of the hot spots in the field of biopharmaceuticals in recent years. At present, the development of peptide-based drugs mainly includes peptide vaccines, anti-tumor peptides, peptide-guided drugs (or peptide-targeted drugs), cytokine mimetic peptides, antibacterial active peptides, diagnostic peptides, etc. Among them, peptide-guided drugs are peptides with binding ability that are fused with cytotoxins or cytokines, etc., and guided to the target site to exert a therapeutic effect while reducing toxic side effects. Peptide-targeted drugs are currently a hot spot in drug development.

[0006] At present, the methods for obtaining polypeptides mainly include: searching for natural unknown polypeptides from nature, and screening from artificially constructed polypeptide libraries. The screening methods include, for example, phage display technology. Phage display technology is to insert different exogenous genes into the coat protein gene of the phage. When the reading frame is correct and the normal function of the coat protein is not affected, the exogenous gene is fused with the phage coat protein, and the progeny phage is reassembled and displayed on its surface to form a phage display library. The polypeptides encoded by the exogenous genes on the surface of the phage still maintain independent spatial structure and biological activity. Subsequently, the target protein can be used to capture phages that can specifically bind to it from the library, and incubate and amplify them by infecting the cell host. After 3 to 5 rounds of panning, phages that can specifically bind to the target protein can be highly enriched, and the amino acid sequence of the polypeptide that can recognize the target molecule can be obtained by sequencing. Summary of the invention

[0007] Problem that the invention aims to solve

[0008] Although there are currently a variety of drugs that target EGFR to treat tumors, the current level of drug development still cannot meet actual clinical needs, and there is still room for development of EGFR-targeted drugs.

[0009] In this regard, the present application provides a polypeptide capable of targeting EGFR, which has a high affinity to EGFR and can provide assistance for the development of EGFR targeted drugs.

[0010] Solutions for solving problems

[0011] In order to solve the above problems, the present invention provides the following technical solutions:

[0012] [1] A polypeptide comprising an amino acid sequence as shown in any one of (a) to (c) below:

[0013] (a) an amino acid sequence as shown in any one of SEQ ID NOs. 1 to 4;

[0014] (b) an amino acid sequence having epidermal growth factor receptor affinity activity and in which one or more amino acids are substituted, deleted or added in the amino acid sequence as shown in any one of SEQ ID NOs. 1 to 4;

[0015] (c) an amino acid sequence having epidermal growth factor receptor affinity activity and having at least 70%, 80%, 90%, 95%, 97%, 98% or 99% sequence identity with the amino acid sequence shown in any one of SEQ ID NOs. 1 to 4.

[0016] [2] The polypeptide according to [1], characterized in that the polypeptide comprises an amino acid sequence as shown in any one of SEQ ID NOs. 1 to 4.

[0017] [3] The polypeptide according to [1] or [2], characterized in that the amino acid sequence of the polypeptide is a sequence as shown in any one of SEQ ID NOs. 1 to 4.

[0018] [4] A polynucleotide encoding the polypeptide according to any one of [1] to [3].

[0019] [5] An expression vector comprising the polynucleotide according to [4];

[0020] Preferably, the expression vector includes a plasmid vector and a viral vector;

[0021] More preferably, the plasmid vector comprises a pET series vector, and / or, more preferably, the viral vector comprises a bacteriophage.

[0022] [6] A host cell comprising the expression vector according to [5];

[0023] Preferably, the host cell includes eukaryotic cells and prokaryotic cells;

[0024] More preferably, the eukaryotic cell comprises yeast, and / or, more preferably, the prokaryotic cell comprises Escherichia coli.

[0025] [7] A method for producing a polypeptide according to any one of [1] to [3], comprising the step of culturing the host cell according to claim 6 and expressing the polypeptide.

[0026] [8] A drug comprising the polypeptide according to any one of [1] to [3];

[0027] Preferably, the drug targets epidermal growth factor receptor;

[0028] More preferably, the drug targeting epidermal growth factor receptor is used to prevent and / or treat tumors;

[0029] Even more preferably, the tumor comprises at least one of lung cancer, colorectal cancer, pancreatic cancer, breast cancer, kidney cancer, ovarian cancer, head and neck cancer, bladder cancer and prostate cancer; more preferably, the tumor is non-small cell lung cancer.

[0030] [9] A detection or diagnosis kit comprising the polypeptide according to any one of [1] to [3].

[0031]

[10] Use of the polypeptide according to any one of [1] to [3] in the preparation of a medicament;

[0032] Preferably, the drug targets epidermal growth factor receptor;

[0033] More preferably, the drug targeting epidermal growth factor receptor is used to prevent and / or treat tumors;

[0034] Even more preferably, the tumor comprises at least one of lung cancer, colorectal cancer, pancreatic cancer, breast cancer, kidney cancer, ovarian cancer, head and neck cancer, bladder cancer and prostate cancer; more preferably, the tumor is non-small cell lung cancer.

[0035] Effects of the Invention

[0036] The present invention provides a polypeptide having a relatively small molecular weight, stable properties, and easy synthesis. Experiments have confirmed that the polypeptide provided by the present invention has a very strong affinity for EGFR, and this affinity is higher than that of existing polypeptides targeting EGFR. The polypeptide provided by the present invention can provide strong support for the development of polypeptide-guided drugs targeting EGFR. DETAILED DESCRIPTION

[0037] The following describes the embodiments of the present invention, but the present invention is not limited thereto. The present invention is not limited to the various structures described below, and various changes can be made within the scope of the invention claim, and the embodiments and examples obtained by appropriately combining the technical means disclosed in different embodiments and examples are also included in the technical scope of the present invention.

[0038] i. Definition of terms

[0039] In the present invention, the term "amino acid" may include natural amino acids, non-natural amino acids, amino acid analogs and all their D and L stereoisomers. The amino acids and their abbreviations and English abbreviations in the present invention are as follows: histidine (His, H), serine (Ser, S), glutamine (Gln, Q), glycine (Gly, G), threonine (Thr, T), phenylalanine (Phe, F), aspartic acid (Asp, D), tyrosine (Tyr, Y), isoleucine (Ile, I), arginine (Arg, R), alanine (Ala, A), glutamine (Gln, Q), valine (Val, V), tryptophan (Trp, W), leucine (Leu, L), methionine (Met, M), asparagine (Asn, N), cysteine ​​(Cys, C), lysine (Lys, K), proline (Pro, P).

[0040] In the present invention, "polypeptide", "protein" and "peptide" are used interchangeably herein to refer to a polymer form of amino acids of any length, which may include coded and non-coded amino acids, chemically or biochemically modified or derived amino acids, and polypeptides with similar peptide backbones.

[0041] In the present invention, "nucleic acid molecule" and "polynucleotide" are used interchangeably to refer to a polymeric form of nucleotides of any length, whether deoxyribonucleotides or ribonucleotides, or their analogs. Polynucleotides can have any three-dimensional structure and can perform any known or unknown function. At the same time, the polynucleotides described in the present invention can be in any form, for example, linear or circular.

[0042] In the present invention, "vector" refers to a nucleic acid carrier into which a polynucleotide can be inserted. When a vector can express the protein encoded by the inserted polynucleotide, the vector is called an expression vector. The vector can be introduced into a host cell by transformation, transduction or transfection, so that the genetic material elements it carries are expressed in the host cell. Non-limiting examples of vectors include, but are not limited to, plasmids, bacteriophages, etc.

[0043] In the present invention, "host cell" refers to a cell into which an expression vector has been introduced. Host cells may include bacteria, microorganisms, plant cells or animal cells. Easily transformed bacteria include members of the Enterobacteriaceae family, such as strains of Escherichia coli or Salmonella, Bacillaceae such as Bacillus subtilis, Pneumococcus, Streptococcus and Haemophilus influenzae. For microorganisms, include Saccharomyces cerevisiae and Pichia pastoris, etc. Suitable animal host cell lines include CHO (Chinese Hamster Ovary Cell Line) and NS0 cells.

[0044] In the present invention, amino acid "addition" refers to adding 1, 2 or 3 amino acids at any position between the C-terminus, N-terminus or C-terminus and N-terminus of the amino acid sequence, and the added amino acids may be all or partly adjacent to each other, or none of the added amino acids may be adjacent to each other; amino acid "deletion" refers to deleting 1, 2 or 3 amino acids from the amino acid sequence; amino acid "replacement" may refer to the replacement of amino acids at 1, 2 or 3 positions of the amino acid sequence by other amino acids, as long as the altered sequence retains the activity of the original amino acid sequence in whole or in part. Amino acid replacement may be a conservative amino acid replacement, which means that compared with the original amino acid sequence, 1, 2 or 3 amino acids are replaced by amino acids with similar or similar properties to form a peptide (conservative variant peptide). Amino acid replacement may also be a non-conservative amino acid replacement.

[0045] In the present invention, "identity" refers to the sequence similarity between two polynucleotide sequences or between two polypeptide sequences. When the positions in the two compared sequences are occupied by the same base or amino acid monomer subunit, for example, if every position of the two DNA molecules is occupied by adenine, then the molecules are homologous at that position. The percent identity between two sequences is a function of the number of matching or homologous positions shared by the two sequences divided by the number of positions compared × 100%. For example, when the sequences are optimally aligned, if 6 out of 10 positions in the two sequences are matched or homologous, then the two sequences are 60% homologous. In general, comparison is performed when the two sequences are aligned to obtain the maximum percent identity.

[0046] In the present invention, "codon optimization" means that the nucleotide sequence encoding the polypeptide has been configured to contain codons preferred by the host cell or organism to improve gene expression in the host cell or organism and increase translation efficiency.

[0047] In the present invention, "treatment" means that after suffering from a disease, by exposing the subject to (e.g., administering) the polypeptide of the present invention or a drug containing the same, the progression of the disease or condition can be delayed or attenuated, including alleviating, relieving or reducing one or more symptoms of the disease or condition, and does not mean that the symptoms of the disease must be completely suppressed.

[0048] In the present invention, "prevention" means that the subject is exposed to (e.g., administered) the polypeptide of the present invention or a drug containing the same before contracting the disease, thereby alleviating the symptoms after contracting the disease compared to the absence of such exposure, and does not necessarily mean that the disease must be completely suppressed.

[0049] In the present invention, "administering" refers to administration by a nurse, health care provider, patient or any other individual, including self-administration. The administration includes not only delivery into the body, but also prescribing, dispensing or assisting delivery in any way.

[0050] In the present invention, "individual", "patient" or "subject" includes mammals. Mammals include, but are not limited to, domestic animals (e.g., cows, sheep, cats, dogs and horses), primates (e.g., humans and non-human primates such as monkeys), rabbits, and rodents (e.g., mice and rats).

[0051] Unless otherwise defined, other technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.

[0052] ii. Peptide

[0053] The present invention provides a polypeptide comprising an amino acid sequence as shown in any one of the following (a) to (c):

[0054] (a) an amino acid sequence as shown in any one of SEQ ID NOs. 1 to 4;

[0055] (b) an amino acid sequence having epidermal growth factor receptor affinity activity and in which one or more amino acids are substituted, deleted or added in the amino acid sequence as shown in any one of SEQ ID NOs. 1 to 4;

[0056] (c) an amino acid sequence having epidermal growth factor receptor affinity activity and having at least 70%, 80%, 90%, 95%, 97%, 98% or 99% sequence identity with the amino acid sequence shown in any one of SEQ ID NOs. 1 to 4.

[0057] The polypeptide provided by the present invention has high affinity with the epidermal growth factor receptor, can target the epidermal growth factor receptor, and has many advantages such as small molecular weight, convenient synthesis, high affinity with EGFR, strong specificity, etc.

[0058] In some preferred embodiments, the polypeptide comprises an amino acid sequence as shown in any one of SEQ ID NOs. 1-4.

[0059] In some specific embodiments, the polypeptide comprises the amino acid sequence shown in SEQ ID NO.1.

[0060] In some specific embodiments, the polypeptide comprises the amino acid sequence shown in SEQ ID NO.2.

[0061] In some specific embodiments, the polypeptide comprises the amino acid sequence shown in SEQ ID NO.3.

[0062] In some specific embodiments, the polypeptide comprises the amino acid sequence shown in SEQ ID NO.4.

[0063] In some preferred embodiments, the amino acid sequence of the polypeptide is a sequence as shown in any one of SEQ ID NOs. 1 to 4.

[0064] In some preferred embodiments, the amino acid sequence of the polypeptide is the sequence shown in SEQ ID NO.1.

[0065] In some preferred embodiments, the amino acid sequence of the polypeptide is the sequence shown in SEQ ID NO.2.

[0066] In some preferred embodiments, the amino acid sequence of the polypeptide is the sequence shown in SEQ ID NO.3.

[0067] In some preferred embodiments, the amino acid sequence of the polypeptide is the sequence shown in SEQ ID NO.4.

[0068] The polypeptide with high affinity to epidermal growth factor receptor provided by the present invention has a small molecular weight, may be composed of only 7 amino acid residues, has stable properties, and has good EGFR affinity and targeting.

[0069] iii. Polynucleotides

[0070] The present invention provides a polynucleotide encoding the above polypeptide.

[0071] The polynucleotide of the present invention can be in the form of DNA or RNA. The DNA form includes cDNA, genomic DNA or artificially synthesized DNA. The DNA can be single-stranded or double-stranded. The DNA can be a coding strand or a non-coding strand.

[0072] In some embodiments, the polynucleotides of the present invention include coding sequences that encode only polypeptides. In some embodiments, the polynucleotides of the present invention include coding sequences of polypeptides and various additional coding sequences. In some embodiments, the polynucleotides of the present invention include coding sequences of polypeptides (and additional coding sequences that may exist) and non-coding sequences.

[0073] The present invention also relates to polynucleotides that hybridize with the above sequences and have at least 50%, preferably at least 70%, and more preferably at least 80% identity between the two sequences. The present invention particularly relates to polynucleotides that can hybridize with the polynucleotides of the present invention under stringent conditions. In the present invention, "stringent conditions" refer to: (1) hybridization and elution at relatively low ionic strength and relatively high temperature, such as 0.2×SSC, 0.1% SDS, 60°C; or (2) addition of denaturants during hybridization, such as 50% (v / v) formamide, 0.1% calf serum / 0.1% Ficoll, 42°C, etc.; or (3) hybridization occurs only when the identity between the two sequences is at least 90%, preferably at least 95%. In addition, the polypeptide encoded by the hybridizable polynucleotide has the same biological function and activity as the polypeptide having epidermal growth factor receptor affinity activity described in the present invention.

[0074] iv. Expression vector

[0075] The present invention provides an expression vector, which contains the above polynucleotide and also contains a suitable promoter or control sequence, etc., which can be used to transform a suitable host cell to enable it to express protein.

[0076] In some embodiments, the expression vector of the present invention includes a plasmid vector or a viral vector; illustratively, the plasmid vector includes a pET series vector, and the viral vector includes a bacteriophage.

[0077] v.Host Cell

[0078] The present invention provides a host cell, which is introduced into or contains the above expression vector.

[0079] In some embodiments, the host cell of the present invention includes a eukaryotic cell or a prokaryotic cell; illustratively, the eukaryotic cell includes yeast, CHO cell or HEK293 cell, and the prokaryotic cell includes Escherichia coli.

[0080] vi. Preparation method

[0081] The present invention provides a method for preparing the above polypeptide, which comprises the steps of culturing the above host cell and expressing the polypeptide.

[0082] The preparation method of the present invention may further comprise the step of isolating and purifying the polypeptide from the culture.

[0083] vii.Medication

[0084] The present invention provides a medicine comprising the above polypeptide.

[0085] In some embodiments, the drug is a drug targeting EGFR.

[0086] In some embodiments, the drug targeting EGFR is used to prevent and / or treat tumors. In some embodiments, the tumor includes at least one of lung cancer, colorectal cancer, pancreatic cancer, breast cancer, kidney cancer, ovarian cancer, head and neck cancer, bladder cancer and prostate cancer.

[0087] In some preferred embodiments, the tumor is non-small cell lung cancer.

[0088] viii. Kit

[0089] The present invention provides a detection or diagnosis kit, which comprises the above polypeptide.

[0090] The kit provided by the present invention can be used to detect EGFR or to diagnose diseases with high EGFR expression, etc., by means of the EGFR targeting property of the polypeptide.

[0091] ix. Methods for detecting EGFR

[0092] The present invention provides a method for detecting EGFR, which comprises contacting the above polypeptide with a sample to be tested and detecting the binding between the two, thereby determining whether EGFR exists in the sample to be tested.

[0093] In some embodiments, the method for detecting EGFR is a method for non-diagnostic or therapeutic purposes. In some embodiments, the method for detecting EGFR is a method for diagnostic or therapeutic purposes.

[0094] x. Purpose

[0095] The present invention provides the use of the above polypeptide in preparing medicines, especially medicines targeting EGFR.

[0096] In some embodiments, the drug targeting EGFR is used to prevent and / or treat tumors.

[0097] In some embodiments, the tumor comprises at least one of lung cancer, colorectal cancer, pancreatic cancer, breast cancer, kidney cancer, ovarian cancer, head and neck cancer, bladder cancer, and prostate cancer.

[0098] In some preferred embodiments, the tumor is non-small cell lung cancer.

[0099] xi. Treatment of tumors

[0100] The present invention provides a method for treating tumors, comprising the step of administering an effective amount of a drug to an individual in need thereof, wherein the drug comprises the above-mentioned polypeptide.

[0101] In some embodiments, the drug is a drug targeting EGFR.

[0102] In some embodiments, the tumor comprises at least one of lung cancer, colorectal cancer, pancreatic cancer, breast cancer, kidney cancer, ovarian cancer, head and neck cancer, bladder cancer, and prostate cancer.

[0103] In some preferred embodiments, the tumor is non-small cell lung cancer.

[0104] Example

[0105] The present invention is further illustrated by examples below, but is not intended to limit the present invention. The specific materials and their sources used in the embodiments of the present invention are provided below. However, it should be understood that these are merely exemplary and are not intended to limit the present invention, and materials identical or similar to the types, models, qualities, properties or functions of the following reagents and instruments can be used to implement the present invention. The experimental methods used in the following examples are conventional methods unless otherwise specified. The materials, reagents, etc. used in the following examples, unless otherwise specified, can all be obtained from commercial sources.

[0106] Example 1: Screening of EGFR-binding polypeptides using phage display technology

[0107] The inventors have previously found that the polypeptide FHLWPNE (SEQ ID NO. 5) has a high affinity with EGFR. In this example, the polypeptide is introduced as a competitive polypeptide to further screen polypeptides that can bind to EGFR. The specific steps are as follows:

[0108] (1) Take 10 μL of phage library (7 peptide library (2×10 13 pfu / mL, Ph.D. TM -7Phage Display PeptideLibrary Kit v2, NEB#E8211-1)(2×10 11 PFU) were added into 390 μL 2% Milk-PBS (PBS with 2% milk) for blocking and shaken at room temperature for 1 h.

[0109] (2) Take 100 μL of streptavidin magnetic beads (Dynabeads TM M-280, Invitrogen, catalog number 11206D), washed 3 times with PBS (1 mL / time), and then blocked with 2% Milk-PBS, and shaken at room temperature for 2 h.

[0110] (3) Add the antigen Biotin-EGFR (Biotinylated Human EGFR Protein, His, Avitag TM,ACRO,EGR-H82E3) 0.5mg / ml was added to 390μL 1mM competitive peptide (FHLWPNE) solution, shaken at room temperature for 2h to obtain antigen + competitive peptide solution. Then, the antigen + competitive peptide solution was added to the sealed phage milk mixture, shaken at room temperature for 1.5h to obtain the phage-antigen mixture.

[0111] (4) Remove the 2% Milk-PBS used for blocking from the magnetic beads, and resuspend them with 200 μL 0.1% PBST-2% Milk (i.e., 0.1% PBST, 2% milk).

[0112] (5) Add the resuspended magnetic beads to the incubated phage-antigen mixture and shake at room temperature for 30 minutes.

[0113] (6) Place the above mixed solution into a magnetic rack. After the magnetic beads are adsorbed to the tube wall, remove the liquid in the tube and then wash the magnetic beads: wash 10 times with 0.1% PBST.

[0114] (7) Allow the magnetic beads to adsorb to the tube wall and remove the PBST in the tube. Add 1 mL of elution buffer (0.2 M Gly-HCl, 1 mg / mL BSA, pH 2.2). After shaking at room temperature for 30 min, immediately add 150 μl of neutralization buffer (1 M Tris-HCl, pH 9.1, filter-sterilized) for neutralization.

[0115] (8) Amplification of the eluate: retain 5 to 10 μL of the eluate for titration and immediately amplify the remaining eluate.

[0116] (9) Inoculate Escherichia coli K12 ER2738 (NEB #E4104S) into 20 mL of LB medium and shake the flask at 37°C and 250 rpm for 1 hour.

[0117] (10) Add phage eluate and continue shaking the flask at 37°C and 250 rpm for 4.5 to 5 hours. Centrifuge at 4°C and 5000g for 10 minutes, resuspend the supernatant with PEG / NaCl (20% (w / v) PEG-8000, 2.5M NaCl), mix gently, and allow the phage to precipitate at 4°C for 2 hours or overnight. Centrifuge, discard the supernatant, resuspend with PBS, centrifuge, transfer the supernatant to a fresh microcentrifuge tube, add 200μL PEG / NaCl, the solution will quickly become turbid, and incubate on ice for 0.5 to 1 hour. Centrifuge, discard the supernatant, and resuspend the precipitate in 0.5mL PBS. Centrifuge for 1 minute to precipitate any remaining insoluble matter. Transfer the supernatant to a fresh tube. This is the eluate after amplification.

[0118] (11) The amplified eluate was titrated using an LB / IPTG / Xgal plate (LB medium + 15 g / L agar powder. Autoclave and cool to below 70°C. Then, 1 ml of IPTG / Xgal was added, mixed and poured onto the plate).

[0119] (12) Count the number of blue spots on the plate to determine the titer.

[0120] (13) Repeat steps (1) to (12) to perform the second, third, and fourth rounds of panning. After four rounds of panning, the eluate is not amplified, and the eluate is titrated to obtain a single plaque for phage sequencing reaction. The titer of the eluate obtained from the fourth round of panning before amplification is measured on an LB / IPTG / Xgal plate. The plaques obtained during the titer determination can be used for sequencing.

[0121] Example 2: Determination of phage titer

[0122] (1) Inoculate a single ER2738 clone in 5-10 mL LB medium and incubate with shaking until mid-logarithmic growth phase (OD600=0.5).

[0123] (2) While the cells are growing, melt the top agarose gel in a microwave oven and dispense into sterile culture tubes, 3 mL per tube. Maintain at 45°C until ready for use.

[0124] (3) Preheat LB / IPTG / Xgal culture plate at 37°C and set aside.

[0125] (4) Dilute the phage 10-fold with LB medium.

[0126] (5) Once the ER2738 culture has reached mid-logarithmic growth phase, aliquot into microcentrifuge tubes, 200 μL per tube.

[0127] (6) Add the serially diluted phage supernatant to the microcentrifuge tube containing the bacterial culture. Add only 10 μL of one dilution to each microcentrifuge tube, vortex rapidly, and incubate at room temperature for 1 to 5 min.

[0128] (7) Transfer to the tube containing the top agarose gel at 45°C, vortex quickly to mix, and immediately pour onto the preheated LB / IPTG / Xgal plate. Gently shake the plate to evenly distribute the top agarose gel.

[0129] (8) Cool the plate for 5 min and incubate it upside down at 37°C overnight.

[0130] (9) Plaque counting is based on a plate with about 100 plaques. The number of plaques multiplied by the dilution ratio gives the titer of phage per 10 μL - plaque forming units (pfu).

[0131] Example 3: Amplification of plaques

[0132] (1) The overnight culture of ER2738 was diluted 1:100 and inoculated into LB medium. 200 μl / well was inoculated into a 96-deep-well bacterial culture plate.

[0133] (2) Use a sterile toothpick or pipette tip to pick up blue plaques into the above 96-well plate, one well for each plaque to be identified. Note: Pick from a plate with less than 100 plaques in total to ensure that each picked plaque contains only one DNA sequence.

[0134] (3) Incubate at 37°C in a shaking incubator for 4.5 to 5 h and store at 4°C until use.

[0135] Example 4: Detection of the binding of selected polypeptides to target molecules by ELISA

[0136] (1) 0.1 M NaHCO3 (pH 8.6) coating antigen: Coat 100 μL of 100 μg / mL target molecule Recombinant Human EGFR Protein (ECD, His Tag) (Sino, Cat: 10001-H08H) onto the ELISA plate at a concentration of 10 μg / ml, 100 μL / well, and coat overnight at 4°C.

[0137] (2) The antigen-coated 96-well ELISA plate was washed three times with 1×PBS / 1‰Tween (Biosharp PBS buffer (ready-to-use dry powder) prepared at 10 mM, pH 7.2-7.4, catalog number BL601A; Tween20, Sigma, catalog number P9416-100 ml); blocked with 2% milk-PBS for 30 min, 350 μl / well; and washed three times with PBST.

[0138] (3) Phage treatment: The packaged phage plate was centrifuged at 4°C and 3000 g for 10 min. 100 μl of the supernatant was transferred to a new 96-well plate (100 μl / well of 2% milk-PBS was added to the plate in advance) and incubated for 1 h.

[0139] (4) Add 200 μl of competitive peptide (FHLWPNE, 0.1 mM) to the ELISA plate and incubate for 1 h; wash three times with PBST;

[0140] (5) Add the blocked phage to the ELISA plate and incubate at room temperature for 1 h; wash three times with PBST;

[0141] (6) Dilute HRP-labeled anti-M13 antibody (Sino, 11973-MM05T-H) at a ratio of 1:2000. Add 100 μl of diluted antibody to each well and incubate at room temperature for 1 h. Wash 6 times with PBST;

[0142] (7) Color development: Add 100 μl of TMB color development solution and color for 2 min.

[0143] (8) Termination: Add 100 μl / well TMB stop solution to terminate the reaction. Reading: Detect OD450nm using an ELISA reader.

[0144] (9) Select positive monoclonal bacterial cultures for sequencing analysis and peptide synthesis.

[0145] Example 5: Peptide affinity determination

[0146] The binding affinity between the peptide and EGFR antigen was obtained by SPR analysis using a surface plasmon resonance instrument.

[0147] (1) Antigen fixation: Take the recombinant target protein Recombinant Human EGFR Protein (ECD, HisTag), Sino, Cat: 10001-H08H, dilute it to 25 μg / mL using 10 mM sodium acetate solution (pH 4.0), and couple it to a dextran surface chip (manufacturer Reichert, catalog number 13206066) so that the final chip antigen binding amount reaches 1500 μRIU.

[0148] (2) Sample preparation: Take the prepared peptide ligand stock solution (5 mM) and dilute it 100 times with PBST (0.05% Tween 20) + 1% DMSO to an initial concentration of 50 μM, and then dilute it 2 times with PBST (0.05% Tween 20) + 1% DMSO, i.e., 50, 25, 12.5, 6.25, 3.125, 1.5625, 0.78125 μM, a total of 7 concentration gradients. Insert a PBST (0.05% Tween 20) + 1% DMSO sample every 3 samples as a blank control.

[0149] (3) Run program: The test samples were injected with the following parameters: set the binding time to 3 min, the dissociation time to 5 min, the regeneration reagent (10 mM Gly-Hcl pH 3.0) binding time to 30 s, the regeneration reagent dissociation time to 1 min, the number of loop repetitions according to the number of samples, the flow rate to 25 μL / min, and the running buffer to PBST (0.05% Tween 20) + 1% DMSO. All experiments were performed at room temperature 25°C, and the samples were kept at 4°C before flowing through the chip. The steady-state fit was determined using the software TraceDrawer (Reichert Technologies) according to the Langmuir 1:1 binding.

[0150] Table 1 shows the binding affinity of the EGFR polypeptide ligands and the competitive polypeptide (SEQ ID NO.5) screened by phage display in the present invention to human EGFR protein. The experimental results show that compared with the original polypeptide (SEQ ID NO.5), the EGFR polypeptide ligands screened by the present invention have better affinity, and the dissociation equilibrium constant KD value is 1.78×10 -5 ~3.39×10 -5 M, which can meet the requirements for developing coupling ligands.

[0151] The affinity test results are shown in Table 1 below:

[0152] Table 1 Affinity test results of peptides and target molecules

[0153] Sequence information KD(M) SEQ ID NO.1 DWNYARL <![CDATA[3.39×10 -5 ]]> SEQ ID NO.2 FLDAHPQ <![CDATA[1.78×10 -5 ]]> SEQ ID NO.3 SLLAHPQ <![CDATA[2.23×10 -5 ]]> SEQ ID NO.4 Wlq <![CDATA[2.71×10 -5 ]]> SEQ ID NO.5 FWF <![CDATA[1.67×10 -4 ]]>

Claims

1. A polypeptide comprising an amino acid sequence as shown in any one of (a) to (c) below: (a) an amino acid sequence as shown in any one of SEQ ID NOs. 1 to 4; (b) an amino acid sequence having epidermal growth factor receptor affinity activity and in which one or more amino acids are substituted, deleted or added in the amino acid sequence as shown in any one of SEQ ID NOs. 1 to 4; (c) an amino acid sequence having epidermal growth factor receptor affinity activity and having at least 70%, 80%, 90%, 95%, 97%, 98% or 99% sequence identity with the amino acid sequence shown in any one of SEQ ID NOs. 1 to 4.

2. The polypeptide according to claim 1, It is characterized in that The polypeptide comprises an amino acid sequence as shown in any one of SEQ ID NOs. 1-4.

3. The polypeptide according to claim 1 or 2, It is characterized in that The amino acid sequence of the polypeptide is a sequence as shown in any one of SEQ ID NOs. 1 to 4. A polynucleotide encoding the polypeptide according to any one of claims 1 to 3.

5. An expression vector comprising the polynucleotide according to claim 4; Preferably, the expression vector includes a plasmid vector and a viral vector; More preferably, the plasmid vector comprises a pET series vector, and / or, more preferably, the viral vector comprises a bacteriophage.

6. A host cell comprising the expression vector according to claim 5; Preferably, the host cell includes eukaryotic cells and prokaryotic cells; More preferably, the eukaryotic cell comprises yeast, and / or, more preferably, the prokaryotic cell comprises Escherichia coli.

7. A method for preparing the polypeptide according to any one of claims 1 to 3, comprising the step of culturing the host cell according to claim 6 and expressing the polypeptide.

8. A drug comprising the polypeptide according to any one of claims 1 to 3; Preferably, the drug targets epidermal growth factor receptor; More preferably, the drug targeting epidermal growth factor receptor is used to prevent and / or treat tumors; Even more preferably, the tumor comprises at least one of lung cancer, colorectal cancer, pancreatic cancer, breast cancer, kidney cancer, ovarian cancer, head and neck cancer, bladder cancer and prostate cancer; more preferably, the tumor is non-small cell lung cancer.

9. A detection or diagnosis kit comprising the polypeptide according to any one of claims 1 to 3.

10. Use of the polypeptide according to any one of claims 1 to 3 in the preparation of a drug; Preferably, the drug targets epidermal growth factor receptor; More preferably, the drug targeting epidermal growth factor receptor is used to prevent and / or treat tumors; Even more preferably, the tumor comprises at least one of lung cancer, colorectal cancer, pancreatic cancer, breast cancer, kidney cancer, ovarian cancer, head and neck cancer, bladder cancer and prostate cancer; more preferably, the tumor is non-small cell lung cancer.